The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2016 | Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway

Name: Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway
Uploaded: 2016-06-03T00:00:00.000Z
Duration: 6 min 11 s
Description: Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

John Hainsworth • 3 Jun 2016

ASCO 2016

Breast Cancer Lung Cancer Skin Cancer

Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.